
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's financial outlook remains robust, with projected product sales increasing from $1.73 billion in 2025 to $2.15 billion in 2026, driven by a diverse pipeline of 35 mRNA development candidates targeting various therapeutic areas. The company bolstered its financial flexibility through a $1.5 billion debt deal and improved manufacturing efficiency, which is expected to enhance gross margins from 30% in 2023 back to 50% in 2025 and potentially expand by an additional 10% over the next three years. Additionally, positive clinical trial results for key programs, including immunotherapies and the mRNA-3927 for propionic acidemia, further establish the potential for long-term revenue growth and sustained market presence.
Bears say
The financial outlook for Moderna's stock appears negative due to a significant decline in COVID vaccine sales, which fell from $18 billion in 2022 to $6.7 billion in 2023, with further reductions in guidance for 2025 amid waning vaccination rates. Additional concerns stem from competition in the respiratory vaccines market and a slow pipeline progress for other therapeutic areas, impacting overall revenue growth potential. Furthermore, projections for COVID-related sales are estimated to decrease substantially from $3.5 billion to $2.5 billion annually as the pandemic transitions to an endemic phase, alongside expectations of low sales in the EU market for 2024 and likely 2025.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares